| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/ANA.410440712 |
| P953 | full work available online at | https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fana.410440712 |
| https://onlinelibrary.wiley.com/doi/pdf/10.1002/ana.410440712 | ||
| P698 | PubMed publication ID | 9749577 |
| P2093 | author name string | P. Jenner | |
| C. W. Olanow | |||
| P433 | issue | 3 Suppl 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Parkinson's disease | Q11085 |
| cell death | Q2383867 | ||
| P304 | page(s) | S72-84 | |
| P577 | publication date | 1998-09-01 | |
| P13046 | publication type of scholarly work | review article | Q7318358 |
| P1433 | published in | Annals of Neurology | Q564414 |
| P1476 | title | Understanding cell death in Parkinson's disease | |
| Understanding cell death in parkinson's disease | |||
| P478 | volume | 44 |
| Q37620482 | A dual-hit animal model for age-related parkinsonism |
| Q46896514 | A model of MPTP-induced Parkinson's disease in the goldfish |
| Q33816818 | A portrait of the Bcl-2 protein family: life, death, and the whole picture |
| Q24293727 | A role for alpha-synuclein in the regulation of dopamine biosynthesis |
| Q40657735 | Activation of phosphoinositide 3-kinase by D2 receptor prevents apoptosis in dopaminergic cell lines |
| Q41841066 | Acute and long‐term response of dopamine nigrostriatal synapses to a single, low‐dose episode of 3‐nitropropionic acid‐mediated chemical hypoxia |
| Q34340531 | Alpha synuclein aggregation: is it the toxic gain of function responsible for neurodegeneration in Parkinson's disease? |
| Q34573229 | Alpha-synuclein targets the plasma membrane via the secretory pathway and induces toxicity in yeast |
| Q35046915 | An inflammatory review of Parkinson's disease. |
| Q41981198 | Anti-Parkinson Activity of Petroleum Ether Extract of Ficus religiosa (L.) Leaves |
| Q35863280 | Anti-oxidant polydatin (piceid) protects against substantia nigral motor degeneration in multiple rodent models of Parkinson's disease |
| Q34186312 | Apoptosis in neurodegenerative disorders |
| Q34289865 | Are dopamine receptor agonists neuroprotective in Parkinson's disease? |
| Q48964363 | Assessment of Glutathione Homeostasis |
| Q36994203 | Astaxanthin Suppresses MPP+-Induced Oxidative Damage in PC12 Cells through a Sp1/NR1 Signaling Pathway |
| Q24307382 | Autoregulation of Parkin activity through its ubiquitin-like domain |
| Q44641452 | BAX protein-immunoreactivity in midbrain neurons of Parkinson’s disease patients |
| Q30846057 | Caloric restriction increases neurotrophic factor levels and attenuates neurochemical and behavioral deficits in a primate model of Parkinson's disease |
| Q35083548 | Caspase-3: A vulnerability factor and final effector in apoptotic death of dopaminergic neurons in Parkinson's disease. |
| Q35172117 | Cell replacement therapy in neurological disease |
| Q36056203 | Chelators in the Treatment of Iron Accumulation in Parkinson's Disease |
| Q44470228 | Commentary: Progressive inflammation as a contributing factor to early development of Parkinson's disease |
| Q35988085 | Comparative Proteomic Analysis of Carbonylated Proteins from the Striatum and Cortex of Pesticide-Treated Mice |
| Q36749222 | Constitutive autophagy: vital role in clearance of unfavorable proteins in neurons. |
| Q49019886 | Crosslinking of alpha-synuclein by advanced glycation endproducts--an early pathophysiological step in Lewy body formation? |
| Q64249418 | Crosstalk between Oxidative Stress and Tauopathy |
| Q35748184 | Cytoplasmic aggregates of phosphorylated extracellular signal-regulated protein kinases in Lewy body diseases |
| Q39977154 | Cytoprotective effect of Valeriana officinalis extract on an in vitro experimental model of Parkinson disease |
| Q39922909 | DJ-1 protects against dopamine toxicity |
| Q35011535 | Demystified. Nitric oxide |
| Q73631978 | Dietary vitamin E and Parkinson's disease: something to chew on |
| Q36819703 | Differences in vulnerability of neurons and astrocytes to heme oxygenase-1 modulation: Implications for mitochondrial ferritin |
| Q37097033 | Differential effects of the dopamine neurotoxin MPTP in animals with a partial deletion of the GDNF receptor, GFR alpha1, gene |
| Q34277399 | Direct observation of the interconversion of normal and toxic forms of α-synuclein |
| Q43875583 | Distinct role for microglia in rotenone-induced degeneration of dopaminergic neurons. |
| Q33283198 | Disturbance of iron metabolism as a contributing factor to SN hyperechogenicity in Parkinson's disease: implications for idiopathic and monogenetic forms |
| Q47792156 | Dopamine induces cell death, lipid peroxidation and DNA base damage in a catecholaminergic cell line derived from the central nervous system |
| Q24683066 | Dopamine-dependent neurodegeneration in rats induced by viral vector-mediated overexpression of the parkin target protein, CDCrel-1 |
| Q64789910 | Drug treatment of Parkinson's disease. Time for phase II |
| Q35812335 | Effects of Antidepressants on DSP4/CPT-Induced DNA Damage Response in Neuroblastoma SH-SY5Y Cells |
| Q35137623 | Effects of aging on glutamate neurotransmission in the substantia nigra of Gdnf heterozygous mice. |
| Q34995130 | Energetics and oxidative stress in synaptic plasticity and neurodegenerative disorders |
| Q39622221 | Enhanced dopamine transporter activity in middle-aged Gdnf heterozygous mice |
| Q77384419 | Enhanced maze performance and reduced oxidative stress by combined extracts of zingiber officinale and ginkgo biloba in the aged rat |
| Q51423787 | Enhanced neuronal expression of the oxidoreductase--biliverdin reductase--after permanent focal cerebral ischemia |
| Q31140077 | Estradiol prevents olfactory dysfunction induced by A-β 25-35 injection in hippocampus |
| Q34523361 | Estrogenic modulation of brain activity: implications for schizophrenia and Parkinson's disease. |
| Q73260280 | Etiology of Parkinson's Disease |
| Q44850278 | Evidence of active microglia in substantia nigra pars compacta of parkinsonian monkeys 1 year after MPTP exposure. |
| Q40549467 | Experimental strategy to identify genes susceptible to oxidative stress in nigral dopaminergic neurons |
| Q48678369 | Expression analysis of genes of ubiquitin-proteasome protein degradation system in MPTP-induced mice models of early stages of Parkinson's disease. |
| Q45081906 | Expression of dopamine and vesicular monoamine transporters and differential vulnerability of mesostriatal dopaminergic neurons |
| Q34325371 | Failure of the ubiquitin-proteasome system in Parkinson's disease |
| Q36667043 | GLP-2 Attenuates LPS-Induced Inflammation in BV-2 Cells by Inhibiting ERK1/2, JNK1/2 and NF-κB Signaling Pathways. |
| Q35616756 | GSTpi expression mediates dopaminergic neuron sensitivity in experimental parkinsonism |
| Q33943273 | Gene transfer of the JNK interacting protein-1 protects dopaminergic neurons in the MPTP model of Parkinson's disease |
| Q37298364 | Geraniol ameliorates the motor behavior and neurotrophic factors inadequacy in MPTP-induced mice model of Parkinson's disease |
| Q31885989 | Glial cell line-derived neurotrophic factor concentration dependently improves disability and motor activity in MPTP-treated common marmosets |
| Q34077007 | Glial cell line-derived neurotrophic factor protects midbrain dopaminergic neurons against lipopolysaccharide neurotoxicity. |
| Q39216202 | Glial cell-line derived neurotrophic factor (GDNF) replacement attenuates motor impairments and nigrostriatal dopamine deficits in 12-month-old mice with a partial deletion of GDNF |
| Q49698299 | Glut9-mediated Urate Uptake Is Responsible for Its Protective Effects on Dopaminergic Neurons in Parkinson's Disease Models |
| Q82907231 | Glutamate induces glutathione efflux mediated by glutamate/aspartate transporter in retinal cell cultures |
| Q38418660 | Glutathione S-transferase T1 and M1 null genotypes and Parkinson's disease risk: evidence from an updated meta-analysis |
| Q37178356 | Glutathione depletion in immortalized midbrain-derived dopaminergic neurons results in increases in the labile iron pool: implications for Parkinson's disease. |
| Q44026095 | Glutathione depletion in nigrostriatal slice cultures: GABA loss, dopamine resistance and protection by the tetrahydrobiopterin precursor sepiapterin |
| Q38834715 | HSP70 mediates survival in apoptotic cells-Boolean network prediction and experimental validation |
| Q45178235 | Hsp70 gene transfer by adeno-associated virus inhibits MPTP-induced nigrostriatal degeneration in the mouse model of Parkinson disease |
| Q30584394 | Hydroxyl radical and superoxide dismutase in blood of patients with Parkinson's disease: relationship to clinical data |
| Q30868164 | Identification of brain proteins that interact with 2-methylnorharman. An analog of the parkinsonian-inducing toxin, MPP+. |
| Q31885597 | Immunosuppressive and non-immunosuppressive immunophilin ligands improve H(2)O(2)-induced cell damage by increasing glutathione levels in NG108-15 cells |
| Q38296498 | Increased dopaminergic neuron sensitivity to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in transgenic mice expressing mutant A53T alpha-synuclein |
| Q34997812 | Induced neurogenesis by endogenous progenitor cells in the adult mammalian brain. |
| Q37036090 | Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease. |
| Q35687315 | Inflammatory Animal Model for Parkinson's Disease: The Intranigral Injection of LPS Induced the Inflammatory Process along with the Selective Degeneration of Nigrostriatal Dopaminergic Neurons |
| Q34795190 | Interplay between oxidative damage, protein synthesis, and protein degradation in Alzheimer's disease |
| Q43003870 | Intranigral LPS administration produces dopamine, glutathione but not behavioral impairment in comparison to MPTP and 6-OHDA neurotoxin models of Parkinson's disease |
| Q37217248 | Intrastriatal lipopolysaccharide injection induces parkinsonism in C57/B6 mice |
| Q43908040 | Involvement of inducible nitric oxide synthase in inflammation-induced dopaminergic neurodegeneration |
| Q85125086 | Iron mediates neuritic tree collapse in mesencephalic neurons treated with 1-methyl-4-phenylpyridinium (MPP+) |
| Q29615656 | Iron, brain ageing and neurodegenerative disorders |
| Q39193255 | JNK and p38 MAPK regulate oxidative stress and the inflammatory response in chlorpyrifos-induced apoptosis |
| Q45032073 | LPS-induced oxidative stress and inflammatory reaction in the rat striatum |
| Q38198207 | LRRK2 and neuroinflammation: partners in crime in Parkinson's disease? |
| Q33709242 | Leads for the development of neuroprotective treatment in Parkinson's disease and brain imaging methods for estimating treatment efficacy |
| Q31030866 | Localization of phosphorylated ERK/MAP kinases to mitochondria and autophagosomes in Lewy body diseases |
| Q30488299 | Long-term consequences of methamphetamine exposure in young adults are exacerbated in glial cell line-derived neurotrophic factor heterozygous mice. |
| Q64273342 | Lymphoproliferation Impairment and Oxidative Stress in Blood Cells from Early Parkinson's Disease Patients |
| Q47101012 | MPTP-induced vulnerability of dopamine neurons in A53T α-synuclein overexpressed mice with the potential involvement of DJ-1 downregulation |
| Q35827966 | Manganese superoxide dismutase protects against 6-hydroxydopamine injury in mouse brains. |
| Q33908238 | Metabolism and functions of glutathione in brain. |
| Q37428097 | Metal chelators coupled with nanoparticles as potential therapeutic agents for Alzheimer's disease |
| Q37781744 | Metals, oxidative stress and neurodegenerative disorders |
| Q23916366 | Mice deficient in TNF receptors are protected against dopaminergic neurotoxicity: implications for Parkinson's disease |
| Q37169187 | Microglia enhance manganese chloride-induced dopaminergic neurodegeneration: role of free radical generation |
| Q26784216 | Mitochondria: A Therapeutic Target for Parkinson's Disease? |
| Q34460675 | Mitochondrial Dysfunction in Parkinson's Disease: Pathogenesis and Neuroprotection |
| Q29398392 | Mitochondrial Polymorphisms Significantly Reduce the Risk of Parkinson Disease |
| Q37203629 | Mitochondrial permeability in neuronal death: possible relevance to the pathogenesis of Parkinson's disease |
| Q29619903 | Molecular Pathways of Neurodegeneration in Parkinson's Disease |
| Q37749063 | Molecular mechanisms of pathogenesis of Parkinson's disease. |
| Q37603401 | Multifunctional roles of enolase in Alzheimer's disease brain: beyond altered glucose metabolism |
| Q34074236 | NO synthase and NO-dependent signal pathways in brain aging and neurodegenerative disorders: the role of oxidant/antioxidant balance. |
| Q33720596 | Nanoparticle and iron chelators as a potential novel Alzheimer therapy |
| Q36161882 | Natural antioxidants for neurodegenerative diseases |
| Q37363138 | Natural antioxidants protect neurons in Alzheimer's disease and Parkinson's disease |
| Q47098715 | Neurochemical and Behavior Deficits in Rats with Iron and Rotenone Co-treatment: Role of Redox Imbalance and Neuroprotection by Biochanin A. |
| Q64854489 | Neurodegenerative disorders: the role of peroxynitrite |
| Q35044751 | Neuroinflammation and α-synuclein dysfunction potentiate each other, driving chronic progression of neurodegeneration in a mouse model of Parkinson's disease. |
| Q36919403 | Neuroinflammatory mechanisms in Parkinson's disease: potential environmental triggers, pathways, and targets for early therapeutic intervention |
| Q33241058 | Neuroprotection from NMDA excitotoxic lesion by Cu/Zn superoxide dismutase gene delivery to the postnatal rat brain by a modular protein vector. |
| Q35817235 | Neuroprotection in Parkinson's disease: an elusive goal |
| Q40776566 | Neuroprotection through delivery of glial cell line-derived neurotrophic factor by neural stem cells in a mouse model of Parkinson's disease. |
| Q34237471 | Neuroprotective effects of D3 dopamine receptor agonists |
| Q40613501 | Neuroprotective effects of the novel D3/D2 receptor agonist and antiparkinson agent, S32504, in vitro against 1-methyl-4-phenylpyridinium (MPP+) and in vivo against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): a comparison to ropinirole. |
| Q34105782 | Neuroprotective signaling and the aging brain: take away my food and let me run. |
| Q36687848 | Neuroreplacement, growth factor, and small molecule neurotrophic approaches for treating Parkinson's disease |
| Q34075997 | Nicotinamide nucleotide transhydrogenase (Nnt) links the substrate requirement in brain mitochondria for hydrogen peroxide removal to the thioredoxin/peroxiredoxin (Trx/Prx) system |
| Q35791943 | Nitration of tau protein is linked to neurodegeneration in tauopathies |
| Q53337561 | Normal cerebrospinal fluid glutathione concentrations in Parkinson's disease, Alzheimer's disease and multiple system atrophy |
| Q34577087 | Novel Regulation of Parkin Function through c-Abl-Mediated Tyrosine Phosphorylation: Implications for Parkinson's Disease |
| Q74115027 | Overexpression of copper/zinc superoxide dismutase does not prevent neonatal lethality in mutant mice that lack manganese superoxide dismutase |
| Q35876266 | Oxidative Stress and Microglial Cells in Parkinson's Disease |
| Q37509229 | Oxidative modifications, mitochondrial dysfunction, and impaired protein degradation in Parkinson's disease: how neurons are lost in the Bermuda triangle |
| Q82029447 | Oxidative stress and Parkinson's disease |
| Q35116171 | Oxidative stress in neurodegenerative diseases: therapeutic implications for superoxide dismutase mimetics |
| Q40672194 | Oxidative stress regulated genes in nigral dopaminergic neuronal cells: correlation with the known pathology in Parkinson's disease |
| Q45227787 | Oxidative stress, induced by 6-hydroxydopamine, reduces proteasome activities in PC12 cells: implications for the pathogenesis of Parkinson's disease |
| Q35963897 | Oxidatively generated DNA damage after Cu(II) catalysis of dopamine and related catecholamine neurotransmitters and neurotoxins: Role of reactive oxygen species |
| Q33848300 | Par-4: an emerging pivotal player in neuronal apoptosis and neurodegenerative disorders |
| Q35625450 | Paraquat and iron exposure as possible synergistic environmental risk factors in Parkinson's disease |
| Q24290518 | Parkin functions as an E2-dependent ubiquitin- protein ligase and promotes the degradation of the synaptic vesicle-associated protein, CDCrel-1 |
| Q48177704 | Parkinson disease: from pathology to molecular disease mechanisms |
| Q24815148 | Parkinson's disease and exposure to infectious agents and pesticides and the occurrence of brain injuries: role of neuroinflammation |
| Q35625447 | Parkinson's disease and inflammatory changes. |
| Q34224578 | Parkinson's disease, pesticides and mitochondrial dysfunction |
| Q39327711 | Parkinson's disease: Microglial/macrophage-induced immunoexcitotoxicity as a central mechanism of neurodegeneration |
| Q36655956 | Parkinson's disease: a complex interplay of mitochondrial DNA alterations and oxidative stress |
| Q34688339 | Parkinson's disease: one biochemical pathway to fit all genes? |
| Q35700596 | Pathogenesis of Parkinson's disease: prospects of neuroprotective and restorative therapies. |
| Q33931980 | Pathologies associated with the p53 response |
| Q37199221 | Pathways to neurodegeneration: mechanistic insights from GWAS in Alzheimer's disease, Parkinson's disease, and related disorders |
| Q33881686 | Peroxynitrite inactivation of tyrosine hydroxylase: mediation by sulfhydryl oxidation, not tyrosine nitration. |
| Q44624548 | Plasma levels of antioxidant vitamins C and E are decreased in vascular parkinsonism |
| Q74230026 | Plasma levels of vitamin E in Parkinson's disease |
| Q35182956 | Potential therapeutic properties of green tea polyphenols in Parkinson's disease |
| Q44551684 | Pramipexole increases vesicular dopamine uptake: implications for treatment of Parkinson's neurodegeneration |
| Q46857211 | Pramipexole protects against H2O2-induced PC12 cell death |
| Q37357416 | Preferentially increased nitration of alpha-synuclein at tyrosine-39 in a cellular oxidative model of Parkinson's disease. |
| Q28138668 | Prospects for new restorative and neuroprotective treatments in Parkinson's disease |
| Q43515328 | Proteasomal function is impaired in substantia nigra in Parkinson's disease |
| Q82029470 | Protein-handling dysfunction in Parkinson's disease |
| Q35941669 | Proteolytic dysfunction in neurodegenerative disorders |
| Q35794541 | Proteomic approach to studying Parkinson's disease |
| Q45269942 | Quantitative 1H magnetic resonance spectroscopic imaging determines therapeutic immunization efficacy in an animal model of Parkinson's disease. |
| Q43656908 | Quantitative analysis of cell death and ferritin expression in response to cortical iron: implications for hypoxia-ischemia and stroke |
| Q38182404 | RBR E3-ligases at work |
| Q36213563 | RGS10 exerts a neuroprotective role through the PKA/c-AMP response-element (CREB) pathway in dopaminergic neuron-like cells |
| Q35166579 | Reactive oxygen species and reactive nitrogen species: relevance to cyto(neuro)toxic events and neurologic disorders. An overview. |
| Q42717387 | Reactive oxygen species regulated mitochondria-mediated apoptosis in PC12 cells exposed to chlorpyrifos |
| Q34243986 | Reactive oxygen/nitrogen species and their functional correlations in neurodegenerative diseases. |
| Q38215181 | Recent updates in the treatment of neurodegenerative disorders using natural compounds |
| Q39817121 | Reciprocal effects of alpha-synuclein overexpression and proteasome inhibition in neuronal cells and tissue |
| Q44588640 | Reciprocal inhibition of p53 and nuclear factor-kappaB transcriptional activities determines cell survival or death in neurons. |
| Q33810589 | Region-specific protein abundance changes in the brain of MPTP-induced Parkinson's disease mouse model |
| Q34781654 | Regulation of Substantia Nigra Pars Reticulata GABAergic Neuron Activity by H₂O₂ via Flufenamic Acid-Sensitive Channels and K(ATP) Channels |
| Q34127988 | Resveratrol protects dopamine neurons against lipopolysaccharide-induced neurotoxicity through its anti-inflammatory actions. |
| Q88968501 | Revisiting the Paraquat-Induced Sporadic Parkinson's Disease-Like Model |
| Q37497595 | Role of ERK1, 2, and 5 in dopamine neuron survival during aging. |
| Q28290234 | Roles for NF-kappaB in nerve cell survival, plasticity, and disease |
| Q28116512 | S-Nitrosylation of parkin as a novel regulator of p53-mediated neuronal cell death in sporadic Parkinson's disease |
| Q36226814 | Section II. The dopamine system |
| Q28576367 | Selective binding of nuclear alpha-synuclein to the PGC1alpha promoter under conditions of oxidative stress may contribute to losses in mitochondrial function: implications for Parkinson's disease |
| Q44048965 | Selective loss of 20S proteasome alpha-subunits in the substantia nigra pars compacta in Parkinson's disease |
| Q34310129 | Self-induced accumulation of glutamate in striatal astrocytes and basal ganglia excitotoxicity |
| Q24797276 | Sensitivity to oxidative stress in DJ-1-deficient dopamine neurons: an ES- derived cell model of primary Parkinsonism |
| Q34297771 | Signaling and gene expression in the neuron-glia unit during brain function and dysfunction: Holger Hydén in memoriam |
| Q38901449 | Single-nucleotide polymorphisms and haplotypes of non-coding area in the CP gene are correlated with Parkinson's disease |
| Q34382885 | Spectroscopic and computational investigation of three Cys-to-Ser mutants of nickel superoxide dismutase: insight into the roles played by the Cys2 and Cys6 active-site residues |
| Q45297477 | Stem and progenitor cell-based therapy of the human central nervous system. |
| Q42508551 | Swainsonine as a lysosomal toxin affects dopaminergic neurons |
| Q44323441 | Synergistic dopaminergic neurotoxicity of the pesticide rotenone and inflammogen lipopolysaccharide: relevance to the etiology of Parkinson's disease. |
| Q38078728 | Targeting dysregulation of brain iron homeostasis in Parkinson's disease by iron chelators |
| Q64777142 | The A53T alpha-synuclein mutation increases iron-dependent aggregation and toxicity |
| Q34322877 | The Function and Mechanisms of Nurr1 Action in Midbrain Dopaminergic Neurons, from Development and Maintenance to Survival |
| Q35577679 | The Hunt for a Cure for Parkinson’s Disease |
| Q52167636 | The catalytic subunit of telomerase is expressed in developing brain neurons and serves a cell survival-promoting function. |
| Q52848620 | The contribution of mutant GBA to the development of Parkinson disease in Drosophila |
| Q39063048 | The novel tetramethylpyrazine bis-nitrone (TN-2) protects against MPTP/MPP+-induced neurotoxicity via inhibition of mitochondrial-dependent apoptosis |
| Q79760117 | The putative neuroprotective role of dopamine agonists in Parkinson's disease |
| Q33543091 | The role of iron in neurodegeneration: prospects for pharmacotherapy of Parkinson's disease |
| Q46967693 | The systemic administration of oleoylethanolamide exerts neuroprotection of the nigrostriatal system in experimental Parkinsonism |
| Q34505750 | Thioredoxin reductase deficiency potentiates oxidative stress, mitochondrial dysfunction and cell death in dopaminergic cells |
| Q37466094 | Tickled PINK1: mitochondrial homeostasis and autophagy in recessive Parkinsonism. |
| Q34763209 | Tissue transglutaminase-induced aggregation of alpha-synuclein: Implications for Lewy body formation in Parkinson's disease and dementia with Lewy bodies |
| Q38771837 | Trichloroethylene exposure aggravates behavioral abnormalities in mice that are deficient in superoxide dismutase |
| Q36727515 | Updates in the pathophysiological mechanisms of Parkinson's disease: Emerging role of bone marrow mesenchymal stem cells |
| Q34032608 | Using 'omics' to define pathogenesis and biomarkers of Parkinson's disease |
| Q40812665 | VIP and peptides related to activity-dependent neurotrophic factor protect PC12 cells against oxidative stress |
| Q48872159 | alpha-Synuclein implicated in Parkinson's disease catalyses the formation of hydrogen peroxide in vitro |
| Q35745729 | alpha-synuclein promotes mitochondrial deficit and oxidative stress |
| Q37137308 | eSNPO: An eQTL-based SNP Ontology and SNP functional enrichment analysis platform |
Search more.